Human Dopaminergic Progenitor Cells

Phase 2Biologic

Human Dopaminergic Progenitor Cells is one of 44 biologic programs targeting Parkinson's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson's DiseaseNot yet recruiting

Early-Onset Parkinson's DiseaseRecruiting

Multiple System AtrophyNot yet recruiting

Parkinson's DiseasePhase 2

Not yet recruiting

Early-Onset Parkinson's DiseasePhase 1

Recruiting

Multiple System AtrophyPhase 1

Not yet recruiting

Competition

Competitive Landscape

50 competitors in Parkinson's Disease

#DrugCompanyPhaseTrials

Bendopa

MMerz North America, Inc.

Approved

13 2

Dayvigo

Eisai

Approved

1 3

Ingrezza

Neurocrine Biosciences

Strattera

3 5

Hytrin

AAbbott

Phase 3

3 6

Glucophage

EMD Serono

Phase 3

2 7

Micardis

Boehringer Ingelheim

Phase 3

1 8

Ketalar

AAultman Health Foundation

Phase 2

2 9

Coreg

Akero Therapeutics

Phase 2

2 10

ABBV-951

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Early-Onset Parkinson's Disease

NCT06608355

Q3 2029

Phase 1/2Recruiting

Parkinson's Disease

NCT06167681

Q4 2030

Phase 2Not yet recruiting

Parkinson's Disease

NCT07028632

Q3 2031

Phase 1Not yet recruiting

Multiple System Atrophy

NCT07289477

Clinical

Trials by Indication[1]

Parkinson's Disease3 trials

The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

Recruiting·IiRegene Therapeutics Co., Ltd.·Phase 1/2·NCT06167681·40 enrolled

The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

Not yet recruiting·IiRegene Therapeutics Co., Ltd.·Phase 2·NCT07028632·30 enrolled

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Recruiting·IiRegene Therapeutics Co., Ltd.·Phase 1·NCT07102342·5 enrolled

Multiple System Atrophy1 trial

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

Not yet recruiting·IiRegene Therapeutics Co., Ltd.·Phase 1·NCT07289477·9 enrolled

Early-onset Parkinson's Disease1 trial

The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease

Recruiting·IiRegene Therapeutics Co., Ltd.·Phase 1·NCT06608355·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Human Dopaminergic Progenitor Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human Dopaminergic Progenitor Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human Dopaminergic Progenitor Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — iRegene Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IiRegene Therapeutics Co., Ltd.

Human Dopaminergic Progenitor Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2029

Q4 2030

Q3 2031

Trials by Indication[1]

Parkinson's Disease3 trials

Multiple System Atrophy1 trial

Early-onset Parkinson's Disease1 trial

References

Drug Info

Quick Facts

Related News